Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in <i>BRCA</i>-mutated <i>HER2</i>-negative metastatic or advanced breast cancer: a network meta-analysis

← Back

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Figure 5. Forest plots comparing OS and ORR for talazoparib, olaparib, and TPC. (A) OS; (B) ORR.